The Frontier

Dr. Devi views dementia disorders like Alzheimer's, vascular, and Lewy body disease as a spectrum, not discrete entities. Most Alzheimer's patients have comorbid brain pathologies.

In Alzheimer's pathology, neuroinflammatory changes may precede amyloid deposition, which then triggers tau and synaptic dysfunction. Devi argues this cascade can be interrupted with early anti-inflammatory lifestyle interventions.

Dr. Devi's diagnostic protocol for high-functioning patients involves lengthy cognitive testing, transcranial Doppler, specialized MRI, amyloid/tau PET scans, DAT scans, and lab tests for APOE genotype and inflammatory markers. She critiques standardized blood tests for amyloid alone.

Amyloid prevalence rises with age: Devi cites community data showing amyloid in 25% of people in their 70s, 30+% in their 80s, and 44% by age 90, often without symptoms. She warns against diagnosing Alzheimer's solely on amyloid biomarkers.

Two copies of the APOE4 allele increase Alzheimer's risk by 60% relative to the wild type. Devi compares this risk level to a BRCA gene for breast cancer.

Devi links women's higher Alzheimer's prevalence to longer post-menopause estrogen deprivation, greater survival post-cardiovascular events, and immunological differences. She notes women often present with depression and language issues, while men show aggression.

Menopause-related cognitive impairment can mimic early Alzheimer's symptoms. Devi has treated this successfully with hormone replacement, cholinesterase inhibitors, and targeted brain exercises.

Dr. Devi developed a slow titration protocol for anti-amyloid monoclonal antibodies to reduce ARIA side effects. In her 4/4 APOE patients, this lowered ARIA incidence to 4%, with only one symptomatic case over five years.

Leqembi and Kisunla are priced at ~$26,000 annually for the drug, plus administration fees ranging from $400 to $10,000 per infusion. Devi notes insurers often reject reimbursement for her slower titration protocol.

In clinical trials, anti-amyloid drugs show small benefits: Devi cites CDR-SB score improvements of 0.3-0.4 points out of 18. She argues early intervention before significant tau pathology yields greater benefit.

Devi's multimodal treatment for dementia includes cholinesterase inhibitors, memantine, valacyclovir for some, immune-modifying drugs, VP shunt for hydrocephalus, and off-label transcranial magnetic stimulation to maintain neuronal connectivity.

Lewy body dementia often coexists with Alzheimer's pathology: autopsy studies show 40% of Alzheimer's patients have Lewy body pathology, and ~30-40% of Lewy body patients have Alzheimer's pathology.

Devi distinguishes Lewy body dementia from Parkinson's by noting Lewy body patients rarely have a classic pill-rolling tremor and often retain insight into their visual hallucinations.